Search
info@tavotek.com
BD@tavotek.com Info@tavotek.com
 

NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

\

Tavotek Pivotal Asset Tavo412 Presented at 2025 AAPS National Biotech Conference

  • Author:
  • Origin:
  • Time of issue:2025-04-27
  • Views:168

Tavotek Pivotal Asset Tavo412 Presented at 2025 AAPS National Biotech Conference

  • Author:
  • Origin:
  • Time of issue:2025-04-27
  • Views:168

T1330-02-09-V2.pdf


Previous: A Summary of Tavotek's Presentations at the 2025 AACR Conference
Next: Tavotek Pivotal Asset Tavo101&Tavo103 Presented at 2025 AAPS National Biotech Conference

Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces FDA Clearance of FIH Clinical Trial for TAVO412
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Pivotal Asset Tavo101&Tavo103 Presented at 2025 AAPS National Biotech Conference
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

727 Norristown Road, 3 Spring House Innovation Park Suite 101, Lower Gwynedd, Pennsylvania 19002

China. Suzhou. Suzhou Industrial Park. Unit 405, Building C2, No. 218, Xinghu Street

© 2023 Tavotek Biotherapeutics All rights reserved.   (267) 405-9426

© 2023 Tavotek Biotherapeutics All rights reserved.(267) 405-9426